Betibeglogene autotemcelMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3149186/fr/zynteglo
2020
false
false
false
France
treatment outcome
betibeglogene autotemcel
infusions, intravenous
genetic therapy
orphan drug production
hematopoietic stem cells
beta-Thalassemia
beta-Thalassemia
hematopoietic stem cell transplantation
beta(A-T87Q) globin
antigens, CD34
betibeglogene autotemcel
evaluation of the transparency committee
beta-Globins

---
https://www.prescrire.org/Fr/3/31/59000/0/2020/ArchiveNewsDetails.aspx
2020
false
false
false
France
French
french abstract
Betibeglogene Autotemcel
betibeglogene autotemcel
beta-Thalassemia
betibeglogene autotemcel

---
https://www.has-sante.fr/jcms/p_3165706/fr/zynteglo
2020
false
false
false
France
beta-Thalassemia
genetic therapy
hematopoietic stem cells
hematopoietic stem cell transplantation
antigens, CD34
beta(A-T87Q) globin
infusions, intravenous
insurance, health, reimbursement
transplantation, autologous
Betibeglogene Autotemcel
betibeglogene autotemcel
betibeglogene autotemcel
evaluation of the transparency committee
beta-Globins

---
https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
beta(A-T87Q) globin
transplantation, autologous
adolescent
adult
beta-Thalassemia
antigens, CD34
orphan drug production
infusions, intravenous
transplantation conditioning
betibeglogene autotemcel
product surveillance, postmarketing
hematopoietic stem cell transplantation
aged
drug interactions
pregnancy
breast feeding
beta-Thalassemia
genetic therapy
transduction, genetic
hematopoietic stem cells
Betibeglogene Autotemcel
betibeglogene autotemcel
beta-Globins

---